会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 92. 发明授权
    • 3,7-dithiaprostanoic acid derivative
    • 3,7-二硫代雄甾烷酸衍生物
    • US6043275A
    • 2000-03-28
    • US288307
    • 1999-04-08
    • Toru MaruyamaShuichi Ohuchida
    • Toru MaruyamaShuichi Ohuchida
    • C07C405/00A01K31/5575
    • C07C405/0033
    • A 3,7-dithiaprostanoic acid derivative of the formula (I) ##STR1## (wherein, R.sup.1 is OH, C1.about.6 alkyloxy, NR.sup.6 R.sup.7 (R.sup.6, R.sup.7 are H, C1.about.6 alkyl.); R.sup.2 is H, OH; R.sup.3 is single bond, C1.about.6 alkylene; R.sup.4 is (i) C1.about.8 alkyl substituted by C1.about.6 alkyloxy, halogen etc., (ii) phenyloxy, C3.about.7 cycloalkyloxy, (iii) furyl, furyloxy, thienyl, thienyloxy, naphthyl, naphthyloxy, phthalanyl, phthalanyloxy, (iv) phenyl, phenyloxy, C3.about.7 cycloalkyl, C3.about.7 cycloalkyloxy substituted by C1.about.6 alkyl etc., (v) furyl, furyloxy, thienyl, thienyloxy, naphthyl, naphthyloxy, phthalanyl, phthalanyloxy substituted by C1.about.6 alkyl etc.; R.sup.5 is H, C1.about.6 alkyl.) can bind PGE.sub.2 receptor (particularly, EP4 subtype receptor) strongly. So, they are useful for the prevention and/or treatment of immunological diseases (autoimmune diseases, rejection after organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, liver damage, nephritis, hypertension, myocardiac ischemia and sleeping disorder etc.
    • 式(I)的3,7-二硫代雄甾烷酸衍生物(其中,R 1为OH,C 1-6烷基氧基,NR 6 R 7(R 6,R 7为H,C 1-6烷基); R 2为H,OH; R 3为单 键,C1差异6亚烷基; R 4是(C 1-6)被C 1-6烷氧基,卤素等所取代的C 1-6烷基,(ii)苯氧基,C3差氮化物7环烷氧基,(iii)呋喃基,呋喃基氧基,噻吩基,噻吩氧基,萘基, (iv)苯基氧基,苯氧基,C 3-6不同的环烷基,由C 1-6烷基取代的C 3-6不饱和的环烷氧基,(v)呋喃基,呋喃氧基,噻吩基,噻吩氧基,萘基,萘氧基,苯酞基, 通过C 1-6烷基等; R 5是H,C 1-6烷基)可以强烈结合PGE 2受体(特别是EP4亚型受体)。 因此,它们可用于预防和/或治疗免疫疾病(自身免疫性疾病,器官移植后排斥反应等),哮喘,异常骨形成,神经元细胞死亡,肝损伤,肾炎,高血压,心肌缺血和睡眠障碍等。 。
    • 93. 发明授权
    • 3,7-dithiaprostanoic acid derivative
    • 3,7-二硫代雄甾烷酸衍生物
    • US5892099A
    • 1999-04-06
    • US13885
    • 1998-01-27
    • Toru MaruyamaShuichi Ohuchida
    • Toru MaruyamaShuichi Ohuchida
    • A61K31/557A61K31/5575A61P1/16A61P11/00A61P37/00A61P43/00C07C405/00C08B37/16C07C177/00
    • C07C405/0033
    • A 3,7-dithiaprostanoic acid derivative of the formula (I) ##STR1## (wherein R.sup.1 is OH, C1-4 alkoxy, NR.sup.6 R.sup.7 (wherein R.sup.6, R.sup.7 are H, C1-4);R.sup.2 is H, OH; R.sup.3 is (i)alkyl, alkenyl, alkynyl (ii) phenyl, cycloalkyl (iii) alkyl, alkenyl, alkynyl substituted by phenyl, cycloalkyl (when R.sup.2 is H, alkyl, alkenyl, alkynyl in (i) or (iii) may be substituted by OH) possesses a binding activity for PGE.sub.2 receptor (especially for EP4). Therefore they are useful for the treatment and/or prevention of immunologic diseases (autoimmune diseases, immunological deficiency diseases, organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, liver damage, nephritis, hypertension, myocardiac ischemia etc.
    • 式(I)的3,7-二磺基雄甾烷酸衍生物(I)(其中R 1是OH,C 1-4烷氧基,NR 6 R 7(其中R 6,R 7是H,C 1-4); R 2是H,OH R 3为(ⅰ)烷基,烯基,炔基(ⅱ)苯基,环烷基(ⅲ)烷基,链烯基,被苯基取代的炔基,环烷基(当R 2为H时,烷基,烯基,(ⅰ)或(ⅲ)中的炔基) 被OH取代)具有PGE2受体(特别是EP4)的结合活性,因此可用于治疗和/或预防免疫疾病(自身免疫疾病,免疫缺陷病,器官移植等),哮喘,异常骨 形成,神经元细胞死亡,肝损伤,肾炎,高血压,心肌缺血等。
    • 97. 发明授权
    • Process for producing 16-substituted prostaglandin es.
    • 生产16-取代的前列腺素的方法。
    • US4841091A
    • 1989-06-20
    • US913889
    • 1986-09-29
    • Toshio TanakaAtsuo HazatoSeizi KurozumiMasahiro Koga
    • Toshio TanakaAtsuo HazatoSeizi KurozumiMasahiro Koga
    • C07C405/00
    • C07C405/0033C07C405/00
    • A novel process for manufacturing 16-substituted .DELTA..sup.7 -prostaglandin Es, which include compounds expressed by the following formula (I), their enanantiomers, or their mixtures of arbitray mixing ratio, ##STR1## wherein R.sup.1 indicates COOR.sup.2, CH.sub.2 OR.sup.3, in which R.sup.2 indicates a hydrogen atom, a dubstituted or unsubstituted C.sub.1 -C.sub.10 alkyl group, a substituted or unsubstituted C.sub.3 -C.sub.10 cycloalkyl group, or a substituted or unsubstituted phenyl group, and R.sup.3 indicates a hydrogen atom, a tri(C.sub.1 -C.sub.7) hydrocarbon silyl group, a group which forms an acetal bond together with the oxygen atom of a hydroxyl group, or a C.sub.2 -C.sub.7 acyl group; R.sup.4 and R.sup.5 are identical or different, each representing a hydrogen atom, a tri(C.sub.1 -C.sub.7 ) hydrocarbon silyl group, or a group which forms an acetal bond together with the oxygen atom of a hydroxyl group; R.sup.6 indicates a hydrogen atom, a C.sub.1 -C.sub.4 alkyl group, or a vinyl group; R.sup.7 indicates a linear or branched C.sub.3 -C.sub.8 alkyl group, an alkyenyl group, or an alkynyl group, which may contain an oxygen atom; a phenyl group, a phenoxy group, or a C.sub.3 -C.sub.10 cycloalkyl group, which may be substituted; or a linear or branched C.sub.1 -C.sub.5 alkyl group which is substituted by a C.sub.1 -C.sub.6 alkoxy group, a phenyl group a phenoxy group, or a C.sub.3 -C.sub.10 cycloalkyl group, which may be substituted; and Y indicates CH.sub.2 X or XCH.sub.2, in which X represents an ethylene group, a cis -or trans-vinylene group, or an ethynylene group.
    • PCT No.PCT / JP86 / 00034 Sec。 371日期1986年9月29日第 102(e)1986年9月29日PCT PCT公布1986年1月28日PCT公布。 出版物WO86 / 04330 日期:1986年7月31日。一种用于制备16取代的DELTA 7-前列腺素Es的新方法,其包括由下式(I)表示的化合物,其对映异构体或其混合比的混合物, 其中R1表示COOR2,CH2OR3,其中R2表示氢原子,取代或未取代的C1-C10烷基,取代或未取代的C3-C10环烷基或取代或未取代的苯基,R3表示氢原子, 三(C 1 -C 7)烃甲硅烷基,与羟基的氧原子一起形成缩醛键的基团或C 2 -C 7酰基; R4和R5相同或不同,各自表示氢原子,三(C1-C7)烃甲硅烷基,或与羟基的氧原子一起形成缩醛键的基团; R6表示氢原子,C1-C4烷基或乙烯基; R7表示可含有氧原子的直链或支链C 3 -C 8烷基,链烯基或炔基; 可被取代的苯基,苯氧基或C3-C10环烷基; 或被可被取代的C1-C6烷氧基,苯基苯氧基或C3-C10环烷基取代的直链或支链C1-C5烷基; Y表示CH2X或XCH2,其中X表示亚乙基,顺式或反式亚乙烯基或亚乙炔基。